Skip to content
Human-limitedCardiac peptide bioregulator for heart longevity

Cardiogen

Also indexed as Cardiogen peptide, H-Ala-Glu-Asp-Arg-OH, tetrapeptide-7

Cardiogen is a short synthetic tetrapeptide (Ala-Glu-Asp-Arg) originally developed by the St. Petersburg Institute of Bioregulation and Gerontology in Russia, designed to support cardiac tissue health and function. It acts as a cytoprotective bioregulator targeting cardiomyocytes, promoting cellular repair and reducing age-related deterioration in heart muscle tissue. Research, primarily from Russian preclinical and limited clinical studies, suggests it may help maintain cardiac contractility, reduce fibrosis, and support overall cardiovascular resilience.

Overview

After parenteral administration, the tetrapeptide evades rapid enzymatic degradation due to its compact structure and is distributed systemically. Cardiac tissue uptake is hypothesized to occur via passive diffusion and possibly receptor-mediated endocytosis. Within cardiomyocytes, the peptide reaches the nucleus and modulates gene expression profiles, particularly in aged or stressed cells showing epigenetic silencing of cardioprotective loci. Pharmacokinetics remain poorly characterized in peer-reviewed literature; the half-life is expected to be short (<2 hours) given the peptide's size and lack of PEGylation or protective modifications.

Proposed mechanism

Cardiogen functions as a peptide bioregulator by penetrating cell nuclei and interacting directly with chromatin, modulating gene expression in cardiomyocytes to upregulate proteins associated with cellular repair, anti-apoptotic signaling, and extracellular matrix maintenance. It is believed to activate transcription factors that govern cardiomyocyte survival pathways, potentially via NF-κB modulation and upregulation of cardioprotective proteins such as heat shock proteins. By normalizing protein synthesis in cardiac cells, it may slow or partially reverse age-related functional decline in the myocardium.

What the evidence supports

Human data exists but the trials are small, short-term, or not yet replicated.

Graded Human-limited

Human data that exists but is thin: open-label work, single-arm studies, small cohorts, or observational follow-up without randomisation.

Key citations

Representative primary sources, including results that did not favour the compound.

  1. [1]

    Peptide bioregulation of aging: results and prospects

    · Biogerontology 11(2):139-149 — Khavinson VKh, Goncharova ND, Lapin BA · 2010

  2. [2]

    Short peptides stimulate the functional activity of cardiomyocytes in vitro

    · Bulletin of Experimental Biology and Medicine · 2006

  3. [3]

    Tetrapeptide Ala-Glu-Asp-Arg as a geroprotective drug for patients with cardiovascular diseases

    · Advances in Gerontology (Uspekhi Gerontologii) — Khavinson VKh et al. · 2014

Citation records in this build are illustrative placeholders for the design.

Reference information for research purposes. Not medical advice, and not a recommendation to use any compound. Many entries describe substances that are not approved for human use.